Padmanee Sharma

Padmanee Sharma, MD, PhD, is Professor of Genitourinary Medical Oncology and Immunology, Associate Vice President of Immunobiology, and T.C. and Jeanette D. Hsu Endowed Chair at The University of Texas MD Anderson Cancer Center. She serves as Inaugural Scientific Director of MD Anderson's Immunotherapy Platform. Dr. Sharma is a pioneer of neoadjuvant immune checkpoint therapy and bladder cancer immunotherapy. In 2006-2007, she designed and conducted the first presurgical clinical trial with immune checkpoint therapy (anti-CTLA-4, ipilimumab), establishing the safety and feasibility of neoadjuvant immunotherapy—a paradigm now widely adopted across cancer types. This groundbreaking trial was also the first to test checkpoint blockade in bladder cancer patients, with 25% achieving significant anti-tumor responses including pathologic complete responses (Clin Cancer Res 2010, PMID 20460488). Her subsequent clinical trials with nivolumab in bladder cancer enabled FDA approval for metastatic disease. Dr. Sharma's contributions extend to renal cell carcinoma and prostate cancer. As a key investigator in CheckMate 214, she helped demonstrate that nivolumab plus ipilimumab significantly improved survival versus sunitinib in advanced RCC (NEJM 2018, PMID 29562145, 5,800+ citations), leading to FDA approval in 2018. She also led trials combining tremelimumab with cryoablation (Nat Commun 2021) and exploring combination immunotherapy in metastatic castration-resistant prostate cancer (Cancer Cell 2020). A nationally and internationally renowned physician-scientist, Dr. Sharma collaborates extensively with James P. Allison, the 2018 Nobel Prize winner whom she married in 2014. Their 2020 Nature Reviews Immunology article (PMID 31925406) dissects immune checkpoint mechanisms, bridging clinical observations with fundamental immunology. Elected to ASCI and the 2024 AACR Academy, Dr. Sharma has received the William B. Coley Award, Emil Frei III Award, WISE Award, and Randall Prize. With 65,172 citations across 474 works, she has fundamentally shaped neoadjuvant immunotherapy and genitourinary oncology.

Padmanee Sharma医学博士、哲学博士现任德克萨斯大学MD Anderson癌症中心泌尿生殖系统肿瘤内科与免疫学教授、免疫生物学副主席及T.C. and Jeanette D. Hsu细胞生物学冠名讲席。她担任MD Anderson免疫治疗平台创始科学主任。 Sharma博士是新辅助免疫检查点疗法和膀胱癌免疫治疗的先驱。2006-2007年，她设计并执行了首个使用免疫检查点疗法(抗CTLA-4抗体ipilimumab)的术前临床试验，确立了新辅助免疫治疗的安全性和可行性——这一范式现已广泛应用于多种癌症类型。这一开创性试验也是首个在膀胱癌患者中测试检查点阻断的试验，25%患者获得显著抗肿瘤反应包括病理完全缓解(Clin Cancer Res 2010, PMID 20460488)。她随后在膀胱癌中开展的nivolumab临床试验促成了转移性膀胱癌的FDA批准。 Sharma博士的贡献延伸至肾细胞癌和前列腺癌。作为CheckMate 214的关键研究者，她帮助证明nivolumab联合ipilimumab在晚期RCC患者中显著改善生存相比sunitinib(NEJM 2018, PMID 29562145, 引用5,800+次)，促成2018年FDA批准。她还领导了tremelimumab联合冷冻消融(Nat Commun 2021)和联合免疫治疗在转移性去势抵抗性前列腺癌的试验(Cancer Cell 2020)。 作为享誉国内外的医师科学家，Sharma博士与2018年诺贝尔奖获得者James P. Allison广泛合作(两人于2014年结婚)。他们2020年Nature Reviews Immunology文章(PMID 31925406)剖析免疫检查点机制，将临床观察与基础免疫学相结合。 Sharma博士当选ASCI会员和2024年AACR会士，获William B. Coley奖、Emil Frei III奖、WISE奖和Randall奖。她的474项研究成果获65,172次引用，从根本上塑造了新辅助免疫治疗和泌尿肿瘤学。